Lucent Diagnostics partners with Tempus AI for Alzheimer's blood testing

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Lucent Diagnostics partners with Tempus AI for Alzheimer's blood testing

Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer’s Biomarker Testing into Clinical Workflows

May 6, 2026 8:00 AM EDT

Agreement supports the identification of patients eligible for Alzheimers disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus clinical ordering platform

BILLERICA, Mass.--(BUSINESS WIRE)-- Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimers disease. Through the... More